Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul class="summary-list"><li><keyword id="12095163" type="UNKNOWN" weightage="60" keywordseo="atyr-pharma" source="Orion">aTyr Pharma</keyword> shares have soared as much as 137% this week following notice of a positive clinical trial. </li><li>An early-stage clinical trial for a treatment addressing pulmonary sarcoidosis showed it was safe and tolerable.</li><li>The company will continue developing its lead product candidate ATYR1923 based on the early trial results. </li></ul>Shares of <a href="https://markets.businessinsider.com/stocks/life-stock">aTyr Pharma</a> extended a rally into a second session Tuesday, propelled higher after the biopharma company released promising results about a lung-disease treatment from an early-stage clinical trial. The shares have jumped as much as 137% from Friday's close, hitting an intraday high of $12.97 on Tuesday and touching a market capitalization of $219 million. The stock closed Monday's session up by 67% at $9.15.During Tuesday's trade, the shares bulked as much as 42% before trimming the gain to 22%. The rally got underway after aTyr said Monday its lead product candidate, ATYR1923, met its primary endpoint in demonstrating safety and tolerability in a phase 1b/2a trial of 37 patients with pulmonary sarcoidosis. Pulmonary sarcoidosis is an inflammatory disease that is affecting 200,000 Americans. The trial also showed ATYR1923 produced improvements in, among other things, steroid reduction and lung function compared with placebo. aTyr said its plans to continue developing ATYR1923. It's aiming to meet with the US Food and Drug Administration to present its data and expects to initiate a registrational trial next year. Current treatment options for pulmonary sarcoidosis include corticosteroids and other immunosuppressive therapies, which aTyr says have limited efficacy and are associated with serious side effects, the company said.

A small pharmaceutical company has surged 137% in 2 days after positive results in trials for lung disease treatment

Welcome to 10 Things Before the <keyword id="11907548" type="UNKNOWN" weightage="60" keywordseo="opening-bell" source="Orion">Opening Bell</keyword>. If this was forwarded to you, <a href="https://newsletter.businessinsider.com/join/4np/10-things-opening-bell">sign up here.</a> Plus, download Insider's app for news on the go - <a href="https://apps.apple.com/app/apple-store/id554260576?pt=385758&amp;ct=06292021_newsletters&amp;mt=8amp;mt=8">click here for iOS</a> and<a href="https://play.google.com/store/apps/details?id=com.freerange360.mpp.businessinsider"> here for Android</a>.Let's jump in.1. US fututes are inching up after the softer inflation reading. Oil is rallying again after a draw in inventory levels. <a href="https://markets.businessinsider.com/news/stocks/stock-market-today-us-dow-jones-sp500-inflation-oil-prices-2021-9">Take a look at what's gone on so far today.</a>2. Steve Cohen has agreed to back a new crypto quant-trading firm. Radkl will be receiving funding from Cohen himself, rather than his hedge fund Point72, according to the WSJ. <a href="https://markets.businessinsider.com/news/currencies/cryptocurrency-trading-steve-cohen-radkl-crypto-point-72-2021-9">Here's why the billionaire is pouring money into the digital asset space.</a>3. A math teacher earned an extra $114,000 trading stocks in 2020. Steve Chen used a low-risk investing strategy as a way to supplement his income, and was recently able to quit his job. <a href="https://www.businessinsider.com/trading-stocks-with-low-risk-strategy-options-explained-math-teacher-2021-9">Read about the four pillars of his trading approach. </a>4. On the docket: Inditex S.A., Darktrace PLC, and Weber, all <a href="https://markets.businessinsider.com/earnings-calendar">reporting.</a> 5. Cathie Wood predicts bitcoin will hit $500,000. The Ark Invest CEO also said the firm's confidence in ether has gone up dramatically, and<a href="https://markets.businessinsider.com/news/currencies/cathie-wood-elon-musk-gary-gensler-bitcoin-price-prediction-ark-2021-9"> voiced praise</a> for Elon Musk. <a href="https://markets.businessinsider.com/news/currencies/cathie-wood-bitcoin-price-prediction-jump-500000-ether-confidence-high-2021-9">Here's how Wood plans to structure her firm's crypto portfolio. </a>6. The S&amp;P 500 may get a 10% correction in the near-term, says Morgan Stanley's stock chief. Mike Wilson said the index's relentless 2021 surge may be misleading, and a weakness in the market may reveal itself soon. <a href="https://markets.businessinsider.com/news/stocks/stock-market-outlook-sp500-correction-bearish-mike-wilson-2021-9">See his full comments here.</a>7. The SEC may prohibit trading of 270 Chinese companies by 2024. Per an op-ed by Gary Gensler, the SEC will do so unless overseas companies open their books for auditing. <a href="https://markets.businessinsider.com/news/stocks/sec-chinese-stock-regulation-outlook-restrictions-financial-auditing-gary-gensler-2021-9">Read what else the SEC chairman's said on China. </a>8. A small pharmaceutical company jumped 137% in two days after positive results in lung disease trials. aTyr Pharma reported a positive clinical trial for early-stage pulmonary sarcoidosis, causing stock shares to spike. <a href="https://markets.businessinsider.com/news/stocks/atyr-stock-price-lung-disease-pulmonary-sarcoidosis-atyr1923-fda-trial-2021-9">Here's the latest on the upstart pharma company's rally. </a>9. Top crypto experts from the SALT NY conference talk shop: Four of the most influential crypto strategists - including Sam Bankman-Fried, founder of FTX and Alameda Research - addressed how crypto opens up immense opportunities. <a href="https://www.businessinsider.com/crypto-investing-industry-outlook-defi-stablecoin-solana-salt-ny-conference-2021-9">Here's what the pros have their eyes on now - and where they predict the industry is heading.</a>10. This tech fund has returned 1,876% to investors over 24 years. Ryan Jacob's firm, Jacob Asset Management, has beat out the S&amp;P 500 by more than triple. <a href="https://www.businessinsider.com/tech-stocks-picks-growth-investing-tips-ryan-jacob-fund-portfolio-2021-9">Here are the five stocks Jacob expects to lead his portfolio into the future.</a>Compiled by Phil Rosen. Feedback? Email <a href="mailto:prosen@insider.com">prosen@insider.com</a> or tweet <a href="https://twitter.com/philrosenn">@philrosenn</a>.Sign up for <a href="https://www.businessinsider.com/subscription/newsletter">more Insider newsletters here</a>.

You Searched For "atyr pharma" and got 2 results

A small pharmaceutical company has surged 137% in 2 days after positive results in trials for lung disease treatment

Carla Mozée

10 things before the opening bell

Phil Rosen

Popular Keywords

Buying Guides